Samantha E. Greasley

Samantha E. Greasley

Auto-generated profile, based on publicly available information

Samantha E. Greasley

Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Science
Verified
Journal Article
Closed access
DODafydd R. Owen
Dafydd R. Owen
CACharlotte M. N. Allerton
Charlotte M. N. Allerton
AAAnnaliesa S. Anderson
Annaliesa S. Anderson
LALisa Aschenbrenner
Lisa Aschenbrenner
MAMelissa Avery
Melissa Avery
YZYuao Zhu
Yuao Zhu
Path to another drug against COVID-19: The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs. Owen et al . report the discovery and characterization of a drug against the main protease involved in the cleavage of polyproteins involved in viral replication. The drug, PF-07321332, can be administered orally, has good selectivity and safety profiles, and protects against infection in a mouse model. In a phase 1 clinical trial, the drug reached concentrations expected to inhibit the virus based on in vitro studies. It also inhibited other coronaviruses, including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus, and could be in the armory against future viral threats. —VV

22 April 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SGSamantha E. Greasley
Samantha E. Greasley
SNStephen Noell
Stephen Noell
OPOlga Plotnikova
Olga Plotnikova
RFRoseAnn Ferre
RoseAnn Ferre
WLWei Liu
Wei Liu
CSClaire M. Steppan
Claire M. Steppan
The COVID-19 pandemic continues to be a public health threat with emerging variants of SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2 and the active protease inhibitor in PAXLOVID (nirmatrelvir tablets and ritonavir tablets). However, the efficacy of nirmatrelvir is underdetermined against evolving SARS-CoV-2 variants. Here, we evaluated the in vitro catalytic activity and potency of nirmatrelvir against the Mpro of prevalent variants of concern (VOCs) or variants of interest (VOIs): Alpha (α, B.1.1.7), Beta (β, B.1.351), Delta (δ, B1.617.2), Gamma (γ, P.1), Lambda (λ, B.1.1.1.37/C37), Omicron (ο, B.1.1.529), as well as the original Washington or wildtype strain. These VOCs/VOIs carry prevalent mutations at varying frequencies in the Mpro specifically for α, β, γ (K90R), λ (G15S), and ο (P132H). In vitro biochemical enzymatic assay characterization of the enzyme kinetics of the mutant Mpros demonstrates that they are catalytically comparable to wildtype. We found that nirmatrelvir has similar potency against each mutant Mpro including P132H that is observed in the Omicron variant with a Ki of 0.635 nM as compared to a Ki of 0.933 nM for wildtype. The molecular basis for these observations were provided by solution-phase structural dynamics and structural determination of nirmatrelvir bound to the ο, λ, and β Mpro at 1.63 to 2.09 Å resolution. These in vitro data suggest that PAXLOVID has the potential to maintain plasma concentrations of nirmatrelvir many-fold times higher than the amount required to stop the SARS-CoV-2 VOC/VOI, including Omicron, from replicating in cells.

26 July 2024 in Science Advances
Verified
Journal Article
Open access
YZYuao Zhu
Yuao Zhu
IYIrina Yurgelonis
Irina Yurgelonis
SNStephen Noell
Stephen Noell
QYQingyi Yang
Qingyi Yang
SGShunjie Guan
Shunjie Guan
RCRhonda Cardin
Rhonda Cardin
To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.

19 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SGSamantha E Greasley
Samantha E Greasley
SNStephen Noell
Stephen Noell
OPOlga Plotnikova
Olga Plotnikova
RFRose Ann Ferre
Rose Ann Ferre
WLWei Liu
Wei Liu
CSClaire M Steppan
Claire M Steppan
The COVID-19 pandemic continues to be a public health threat with emerging variants of SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2 and the active protease inhibitor in PAXLOVID ™ (nirmatrelvir tablets and ritonavir tablets). We evaluated the in vitro catalytic activity and in vitro potency of nirmatrelvir against the main protease (M pro ) of prevalent variants of concern (VOC) or variants of interest (VOI): Alpha (α, B.1.1.7), Beta (β, B.1.351), Delta (δ, B1.617.2), Gamma ( γ , P.1), Lambda (λ, B.1.1.1.37/C37), Omicron (o, B.1.1.529) as well as the original Washington or wildtype strain. These VOC/VOI carry prevalent mutations at varying frequencies in the M pro specifically for: α, β, γ (K90R), λ (G15S) and o (P132H). In vitro biochemical enzymatic assay characterization of the enzyme kinetics of the mutant M pros demonstrate that they are catalytically comparable to wildtype. Nirmatrelvir has similar potency against each mutant M pro including P132H that is observed in the Omicron variant with a Ki of 0.635 nM as compared to a Ki of 0.933nM for wildtype. The molecular basis for these observations were provided by solution-phase structural dynamics and structural determination of nirmatrelvir bound to the o, λ and β Mpro at 1.63 - 2.09 Å resolution. These in vitro data suggest that PAXLOVID has the potential to maintain plasma concentrations of nirmatrelvir many-fold times higher than the amount required to stop the SARS-CoV-2 VOC/VOI, including Omicron, from replicating in cells (1).

1 January 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CGChuangxing Guo
Chuangxing Guo
SKSusan Kephart
Susan Kephart
MOMartha Ornelas
Martha Ornelas
JGJavier Gonzalez
Javier Gonzalez
ALAngelica Linton
Angelica Linton
AFAndrea N. Fanjul
Andrea N. Fanjul

1 August 1997 in Biochemical Society Transactions
Verified
Journal Article
Open access
PDF file
DTD. Tisi
D. Tisi
CTC. Teahan
C. Teahan
SGS. Greasley
S. Greasley
BBBen Bax
Ben Bax
MNM. Neu
M. Neu
HJH. Jhoti
H. Jhoti